1. Home
  2. AXP vs NVO Comparison

AXP vs NVO Comparison

Compare AXP & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Express Company

AXP

American Express Company

N/A

Current Price

$308.39

Market Cap

246.7B

Sector

Finance

ML Signal

N/A

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

N/A

Current Price

$38.65

Market Cap

199.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AXP
NVO
Founded
1850
1923
Country
United States
Denmark
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
246.7B
199.4B
IPO Year
2005
2001

Fundamental Metrics

Financial Performance
Metric
AXP
NVO
Price
$308.39
$38.65
Analyst Decision
Buy
Hold
Analyst Count
30
14
Target Price
★ $371.12
$46.15
AVG Volume (30 Days)
2.5M
★ 11.5M
Earning Date
10-23-2026
11-04-2026
Dividend Yield
1.23%
★ 3.36%
EPS Growth
★ 9.78
N/A
EPS
★ 8.81
N/A
Revenue
★ $27,819,000,000.00
N/A
Revenue This Year
$18.66
N/A
Revenue Next Year
$9.03
$1.35
P/E Ratio
$34.96
★ $13.60
Revenue Growth
★ 13.44
N/A
52 Week Low
$290.97
$35.12
52 Week High
$387.49
$64.16

Technical Indicators

Market Signals
Indicator
AXP
NVO
Relative Strength Index (RSI) 42.24 36.02
Support Level $301.54 $38.02
Resistance Level $319.24 $39.58
Average True Range (ATR) 5.18 0.71
MACD 1.15 0.12
Stochastic Oscillator 55.14 40.00

Price Performance

Historical Comparison
AXP
NVO

About AXP American Express Company

American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. It operates in four segments: US consumer services, US commercial services, international card services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: